Variation on PSMA receptor expression over time in prostate cancer

Variation on PSMA receptor expression over time in prostate cancer - PRET - PSMA Receptor Expression over Time

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46835

Enrollment

Registered

2018-08-24

Start date

2019-01-21

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: primaire prostate cancer patients, written informed concent, tumour larger then 1cm, eligible for PET/CT (cT3/Gleason score >7/ PSA >20 ng/mL)

Exclusion criteria

Exclusion criteria: contra-indications for PET/CT scan, therapy scheduled between scans, no PSMA expression on first PET-scan (exclusion for second scan)

Design outcomes

Primary

Measure	Time frame
The main study endpoint is to evaluate the PSMA expression variation at 4 week intervals.	—

Secondary

Measure	Time frame
The secondary endpoint is to determine the optimal time between 68Ga-PSMA injection and prostate surgery for future image-guided surgery.	—

Countries

Netherlands

Outcome results